In particular, B7-H3 expression has been characterized as a prevalent checkpoint on primary prostate tumors [17], correlates with prostate cancer progression and poor outcomes [18, 19], and was unchanged in the tumor microenvironment after treatment with androgen receptor signaling inhibitors (ARSI) enzalutamide or abiraterone acetate plus prednisone [20]. The gene discussed is CD276; the disease is neoplasm.